GlobeNewswire: CV Sciences, Inc. Contains the last 10 of 190 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:19:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/05/16/2443989/0/en/CV-Sciences-Inc-Reports-First-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. Reports First Quarter 2022 Financial Results2022-05-16T13:00:00Z<![CDATA[SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022.]]>https://www.globenewswire.com/news-release/2022/05/12/2441794/0/en/CV-Sciences-Inc-to-Announce-First-Quarter-2022-Results-On-May-16-2022.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. to Announce First Quarter 2022 Results On May 16, 20222022-05-12T11:00:00Z<![CDATA[SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.]]>https://www.globenewswire.com/news-release/2022/03/31/2414353/0/en/CV-Sciences-Inc-Reports-Fiscal-Year-End-2021-Financial-Results.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results2022-03-31T20:05:00Z<![CDATA[SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021.]]>https://www.globenewswire.com/news-release/2022/03/28/2411383/0/en/CV-Sciences-Inc-to-Announce-Fourth-Quarter-and-Full-Year-2021-Results-on-March-31-2022.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 20222022-03-28T20:05:00Z<![CDATA[SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.]]>https://www.globenewswire.com/news-release/2022/03/11/2401999/0/en/UPDATE-CV-Sciences-Adds-PlusCBD-Relief-Softgels-to-Wellness-Line-of-CBD-Products.html?f=22&fvtc=4&fvtv=38855UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products2022-03-11T17:59:44Z<![CDATA[New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness]]>+PlusCBD Relief SoftgelsCV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Productshttps://www.globenewswire.com/news-release/2022/03/08/2399054/0/en/CV-Sciences-Adds-PlusCBD-Relief-Softgels-to-Wellness-Line-of-CBD-Products.html?f=22&fvtc=4&fvtv=38855CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products2022-03-08T14:11:33Z<![CDATA[New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness]]>+PlusCBD Relief SoftgelsCV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Productshttps://www.globenewswire.com/news-release/2022/01/11/2364780/0/en/CV-Sciences-Inc-Announces-Launch-of-PlusCBD-Pain-Relief-Topicals.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. Announces Launch of +PlusCBD™ Pain Relief Topicals2022-01-11T13:00:00Z<![CDATA[+PlusCBD™ expands product offerings to include four new topicals that provide targeted pain relief +PlusCBD™ expands product offerings to include four new topicals that provide targeted pain relief]]>+PlusCBD™ Pain Relief Arthritis Cream+PlusCBD™ Pain Relief topicalshttps://www.globenewswire.com/news-release/2022/01/05/2361626/0/en/CV-Sciences-Inc-Announces-New-Distribution-Agreement-with-GNC.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. Announces New Distribution Agreement with GNC2022-01-05T13:00:00Z<![CDATA[Expands Distribution to 770 GNC Locations Nationwide Expands Distribution to 770 GNC Locations Nationwide]]>CV Sciences Top Selling Ingestible Products+PlusCBD™ Products Available at GNChttps://www.globenewswire.com/news-release/2021/11/30/2343594/0/en/CV-Sciences-Inc-Appoints-Haskell-White-LLP-as-Auditor.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. Appoints Haskell & White LLP as Auditor2021-11-30T21:30:00Z<![CDATA[SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has appointed Haskell & White LLP ("H&W") as the Company's new independent registered public accounting firm.]]>https://www.globenewswire.com/news-release/2021/11/15/2334298/0/en/CV-Sciences-Inc-Announces-Convertible-Note-Financing.html?f=22&fvtc=4&fvtv=38855CV Sciences, Inc. Announces Convertible Note Financing2021-11-15T13:25:00Z<![CDATA[SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the sale and issuance of convertible notes due 2022 in the aggregate original principal amount of $1.06 million. Upon our filing with the Securities and Exchange Commission of an additional prospectus supplement and supplemental indenture and our satisfaction of certain other closing conditions, we may elect to offer and sell up to and additional $4,240,000 in aggregate principal amount of notes at additional closings, resulting in potential gross proceeds for this offering and such additional offerings, of approximately $5.3 million.]]>